DEVELOPMENT OF A REVERSIBLE CLOTTING FACTOR FILTER

可逆凝血因子过滤器的开发

• 批准号: 6340230
• 负责人: KENNETH A SOLEN
• 金额: $ 9.99万
• 依托单位: THROMBODYNE, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2002-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6340230
• 关键词: affinity chromatography; arteriovenous shunt surgery; bioengineering /biomedical engineering; biomaterial compatibility; biomedical equipment development; biomedical equipment safety; blood coagulation; blood filtration; blood tests; cardiovascular disorder prevention; clotting factor; embolism; extracorporeal circulation; hemostasis; heparin; intermolecular interaction; medical complication; nonhuman therapy evaluation; physical separation; plasmapheresis; protamines; protein reconstitution; sheep; surface coating; surface property; surgery material /equipment

DESCRIPTION (Applicant's Description Verbatim): Anticoagulation of blood is necessary for prevention of clotting and/or thromboembolism during extracorporeal circulation. Conventionally, anticoagulation is achieved by administering heparin and reversed by neutralizing with protamine. Both of these procedures may have potential pathological consequences. The applicants have conceived an approach that will obviate the need for heparin as well as protamine. They have developed a clotting factor filter, and through in-vitro studies, demonstrated that it is possible to reversibly bind to a solid substrate certain key clotting factors (prothrombin complex) and thus remove those factors from circulating blood. This renders the blood hypocoagulable. They have also worked out a strategy to harvest the bound clotting factors and return these autologous factors to the blood, thereby restoring its clotting function. This is a proposal to explore the possibility of using the clotting factor filter in an ex-vivo configuration, and thus test the feasibility of: i) rendering the circulating blood hypocoagulable in vivo and ii) establishing that bound clotting factors can be safely returned to the circulating blood in vivo. Success of the proposed experiments will lead to the development of a clotting factor filter for clinical application. PROPOSED COMMERCIAL APPLICATIONS: The proposed research will lead to the development of a simple device that may present an alternative to the current coagulation management with heparin for extracorporeal circulation. This device will obviate the need for both heparin and protamine.

描述（申请人的逐字描述）：血液的抗凝作用是 预防凝血和/或血栓栓塞所必需的 体外循环。传统上，抗凝作用是通过 给予肝素并通过鱼精蛋白中和来逆转。两者都 这些程序可能会产生潜在的病理后果。 申请人设想了一种方法，无需 肝素以及鱼精蛋白。他们开发了一种凝血因子过滤器，并且 通过体外研究，证明可以可逆地结合 某些关键凝血因子（凝血酶原复合物）和固体基质 从而从循环血液中去除这些因素。这使得血液 低凝。他们还制定了一项策略来收获束缚 凝血因子并将这些自体因子返回到血液中，从而 恢复其凝血功能。这是一个探索可能性的提议 在体外配置中使用凝血因子过滤器，从而测试 i) 使循环血液在体内低凝的可行性 ii) 确定结合的凝血因子可以安全地返回到 体内循环血液。拟议实验的成功将导致 开发用于临床应用的凝血因子过滤器。 拟议的商业应用： 拟议的研究将导致开发一种简单的设备，该设备可能会替代目前使用肝素进行体外循环的凝血管理。该装置将不再需要肝素和鱼精蛋白。